The Clinical and Hemodynamic Course of Cardiogenic Shocks Hospitalized in Critical Care

Recruiting

• Conditions: Cardiogenic Shock

• Registration Number: NCT05752383
• Lead Sponsor: Centre Hospitalier Universitaire, Amiens

Brief Summary

Cardiogenic shock is a frequent reason for hospitalization in critical care units, with high mortality (50%). Several French registries have been created to improve knowledge of the prognostic factors of cardiogenic shock. In recent years, temporary mechanical circulatory support has become more important in cardiogenic shock. The monitoring of catecholamines is also performed with a global score: the vaso-inotropic score. The purpose of our study is to consider using these new data and techniques to create a cohort of cardiogenic shock within our critical care unit.

This observational study is based on clinical, biological, and hemodynamic data recorded during the ICU stay of patients for cardiogenic shock.

The primary endpoint is the relationship between the hemodynamic evolution of cardiogenic shock and in-hospital mortality.

Detailed Description

Not available

Study Timeline

• Status Verified: 2023-01
• Study Start: 2023-01-24
• Study First Submitted: 2023-01-24
• Study First Submitted QC: 2023-02-21
• Last Update Submitted: 2023-02-21
• Study First Posted: 2023-03-02
• Last Update Posted: 2023-03-02
• Primary Completion: 2028-01
• Study Completion: 2029-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 500

Inclusion Criteria

• Patients hospitalized in ICU for cardiogenic shock
• Patient with cardiogenic shock as defined by the FRENSCHOCK2 study criteria

Exclusion Criteria

• Patient with cardiogenic shock in the context of septic shock and hemorrhagic shock

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Percentage of in-hospital mortality after cardiogenic shock	5 years
Vaso-inotropic score after cardiogenic shock	5 years	vasoactive-inotropic score (VIS) Maximal VIS (VISmax) is calculated using the highest doses of vasoactive and inotropic medications administered.; VISmax categories: 0-5, \>5-15, \>15-30, \>30-45, and \>45 points.

Trial Locations

Locations (1)

CHU Amiens Picardie; 🇫🇷 Amiens, France